Percepta® Nasal Swab


What is the test?

Objective tools are needed to assess the risk of lung cancer in patients with detected lung nodules

Approximately 1.6 million lung nodules are detected every year with many requiring further evaluation to distinguish between malignant and benign.1

What is Percepta Nasal Swab?

It is a first-of-its-kind, office-based genomic test that objectively classifies lung cancer risk in an identified lung nodule of patients that are ever-smokers. The test result can provide guidance on which patients can safely avoid unnecessary invasive procedures or undergo further workup to confirm their diagnosis.

Percepta Nasal Swab uses a simple and convenient nasal brushing to objectively evaluate suspicious lung nodules

Graphical representation of a nasal swab brushing and collection tube



of low-risk patients underwent an invasive procedure to evaluate a lung nodule that was found to be benign.2


of lung cancer patients receive 2 or more biopsies, delaying the time to diagnosis.3

Sample collection

Graphical representation of two gloved hands collecting a nasal swab brushing from a person

A simple nasal swab brushing just past the inferior nasal turbinate is used to collect a sample, which is sent to Veracyte.

Test results

Graphical representation of a person in a CT scanner

Low risk

Monitor with low dose CT

Graphical representation of two lungs with a bronchoscope reaching towards a lung nodule

Moderate risk

Consider non-surgical tissue sampling inclusive of bronchoscopy

Graphical representation of a scalpel and a syringe.

High risk

Consider sending patients for direct surgery and/or treatment

Percepta Nasal Swab Evidence​


A Nasal Swab Classifier to Evaluate the Probability of Lung Cancer in Patients with Pulmonary Nodules

Carla Lamb, MD, Kim Rieger-Christ, PhD., et al.
CHEST Journal

The Percepta Nasal Swab test determines lung cancer risk of malignancy with high accuracy in individuals who smoke or previously smoked and have a pulmonary nodule. In a study of 312 patients, the classifier identified patients as low risk for cancer with a 97% sensitivity while identifying high risk patients with a 92% specificity. Performance was maintained across lung cancer sub-types, lung nodule size, and degrees of smoking exposure. Classifier guided decision making could lead to fewer diagnostic procedures in patients without cancer and more timely treatment in patients with lung cancer.


1. Gould et al. ATS Journal, 2015.
. Tanner NT et al. CHEST, 2015.
. Zhang Y, et al. Lung Cancer Management, 2020.